Page 20 - Coronavirus Vaccine

First Indian intranasal Covid-19 vaccine to be launched on Jan 26

Homegrown vaccine maker Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC, the first of its kind in India, on Jan 26, the company's chairman and managing director Krishna Ella said

Multilateral bodies must join hands to deal with future outbreaks: SII CEO

Vaccine maker Serum Institute of India CEO Adar Poonawalla has called for global harmonisation or regulatory standards and said that cooperation among multilateral organisations is a must for dealing with future outbreaks. Speaking during the World Economic Forum Annual Meeting 2023, he said he is optimistic about the cooperation. As several leaders here warned against any complacency on the Covid front, Poonawalla said, "We need to keep educating people and dispel vaccine hesitancy". Serum Institute of India (SII) emerged as one of the largest vaccine makers in the world during the pandemic. Poonawalla pitched for advancing vaccine equity and global harmonisation of regulatory standards to allow vaccine manufacturers to make a better real-time impact. "Today, we go through a WHO approval process, you don't want every individual country asking for their own process and clinical trials. We have to be able to accept one level of standard," he added. Poonawalla said he is hopeful th

Coalition sets 100-day goal for faster, equitable pandemic response

They also discussed how to overcome political obstacles to ensure vaccines are made more readily available to all

Covid immunity lasts at least a year after infection plus shots: Study

Boosters conferred an additional 6 months of protection

SII seeks inclusion of Covovax in CoWIN portal as booster dose for adults

Covovax is manufactured through technology transfer from Novavax

Covid-19: Serum's Covovax gets the nod as a mix-and-match booster shot

Experts say no current vaccine protects against sub-lineages of Omicron

Media report on 'side-effects of Covid vaccines' ill-informed: Health Min

Citing an RTI response, a recent news report had claimed that ICMR and CDSCO officials have admitted to side-effects of Covid-19 vaccines, citing a plethora of ramifications arising out of them

SII's Covid vaccine Covovax gets heterologous booster dose approval

Covovax can now be used as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin

No new Covid case in Delhi in a day for first time since pandemic began

The two months saw hospitals and family members of patients scrambling for oxygen and doctors being burdened beyond their capacities

Coronavirus XBB.1.5 variant cases rise to 26 in India: INSACOG data

The INSACOG data also showed that 14 cases of BF.7 strain which is apparently driving China's Covid-19 wave have been found in India

Govt exempts customs duty on imports of Covid-19 vaccines till March 31

Currently, Covid vaccines administered in India include Covishield, Covaxin, Sputnik V, Corbevax and Covovax

SII's free Covishield supply to govt: First 8 mn doses set for dispatch

Amid a rise in Covid cases in some countries, Serum Institute of India has started supply of Covishield to the Centre free of cost with the first lot of 80 lakh doses set to be dispatched from Saturday, official sources said. Since the launch of the anti-Covid vaccination drive, SII has so far provided 170 crore doses of Covishield to the government. According to an official source, Prakash Kumar Singh, Director Government and Regulatory Affairs at Serum Institute of India, had written to Union Health Ministry mentioning that the Pune-based firm will provide two crore doses of Covishield vaccine worth Rs 410 crore to the Government of India free of cost. The Health Ministry has issued a consignee list for the supply of 80 lakh doses of Covishield which will be supplied by the company Saturday, an official source said.

Pfizer bivalent Covid shot linked to strokes in ppl 65 & older: Prelim data

The potential risk with Pfizer's vaccine was not seen in other safety databases, nor was it seen with Moderna Inc.'s Covid vaccine, the officials said in a statement

Omicron new subvariant accounts for 43% new Covid-19 infections in US

Omicron new subvariant XBB.1.5 is estimated to account for 43 per cent of the Covid-19 cases in the US for the week ending January 14, according to data released Friday by the US CDC

Piyush Goyal calls for redoubling efforts at WTO for TRIPS waiver

In June last year, members of the WTO agreed to grant a temporary patent waiver for the manufacturing of Covid-19 vaccines for five years

Covid cases in China touch 900 million, hospitals crowded with patients

The report estimates that 64 per cent of the country's population has the virus, BBC said

Novel spray that could prevent COVID-19 infection developed: Researchers

Researchers have created new molecules that can be sprayed into the nose to block the SARS-CoV-2 virus from entering the lungs and causing infection. The COVID-19 virus enters the body through the lungs when people breathe, resulting in illness. Engineers at the Johns Hopkins University in the US have now created thin, thread-like strands of molecules called supramolecular filaments capable of blocking the virus in its tracks. "The idea is that the filaments will work like a sponge to absorb the COVID-19 virus and other viruses before they have the chance to bind to cells in our airways," said Honggang Cui, an associate professor at Johns Hopkins Whiting School of Engineering. "Even if the therapeutic can block the virus for an hour or two, that can be helpful when people must be in a public setting," said Cui, who led the research published in the journal Matter. The key to this approach is the way that the filaments carry a receptor called angiotensin converting enzyme-2, or ACE

Two American tourists test Covid-19 positive in UP's Agra: Official

Till now two residents of Agra -- one who returned from China and another one from USA -- tested Covid-19 positive

A chance to reclaim the health of humanity

India's presidency of G-20 is a unique opportunity for the global community to build a consensus around a guiding philosophy that collaboration has a much higher value than competition in healthcare

Govt panel recommends market authorisation for Covovax jab as booster dose

Covovax is manufactured through technology transfer from Novavax